CagriSema is Novo Nordisk's attempt to answer a specific question that has come to define the obesity drug race: if semaglutide reshaped the field with 15% weight loss, and tirzepatide raised the bar with 20%+, what does the next-generation Novo Nordisk product look like? The answer is a fixed-dose combination of two peptides in one injection — cagrilintide, a long-acting amylin analog, plus semaglutide, the GLP-1 agonist Novo already had on the shelf — combining two complementary satiety pathways into a single weekly subcutaneous dose.
The Phase 3 REDEFINE-1 trial, which read out in December 2024, delivered a result that was both a genuine scientific success and a commercial disappointment: roughly 22.7% average weight loss at 68 weeks in adults with obesity without diabetes — a strong number in absolute terms, but below the internal bar Novo Nordisk had set and below the level many analysts had been pricing in. The market reaction was sharp; the science is more nuanced. This deep dive walks through the biology, the trial data, and the pipeline context.
⚕️ Regulatory notice. CagriSema is investigational. It is not approved by the FDA, EMA, or any other regulatory agency. It is being evaluated in Phase 3 clinical trials for obesity and type 2 diabetes. Nothing in this article is medical or investment advice.
What Is CagriSema?
CagriSema is a fixed-dose combination peptide product containing two distinct active ingredients:
- Cagrilintide, a long-acting analog of the human pancreatic hormone amylin, engineered by Novo Nordisk for weekly dosing.
- Semaglutide, the GLP-1 receptor agonist already marketed by Novo Nordisk as Ozempic (diabetes) and Wegovy (obesity).
Both peptides are combined into a single once-weekly subcutaneous injection, at ratios of 2.4 mg cagrilintide + 2.4 mg semaglutide at the top dose studied in Phase 3.
The biological rationale is pathway complementarity. GLP-1 and amylin are both satiety hormones, but they act through substantially different central nervous system circuits and peripheral mechanisms. GLP-1 primarily reduces appetite via the hindbrain and hypothalamus and slows gastric emptying. Amylin — released from pancreatic beta cells alongside insulin — suppresses glucagon secretion after meals, further slows gastric emptying, and activates distinct brainstem nuclei to promote satiety. Adding amylin to GLP-1 is, in theory, a way to engage a second independent satiety axis that does not fully overlap with the first.
Cagrilintide, in particular, was designed to be a long-acting analog that does not fibrillate the way native amylin does (native amylin famously forms islet amyloid in type 2 diabetes, which is why the first approved amylin analog, pramlintide, required three-times-daily dosing and had limited uptake). Cagrilintide solved the half-life and fibrillation problems and enabled weekly dosing — which is what made the combination with weekly semaglutide practical in the first place.
Mechanism of Action
Breaking down the mechanisms of the two components:
Semaglutide (GLP-1 receptor agonist).
- Activates GLP-1 receptors in the hypothalamus, brainstem, and vagal afferents to reduce appetite.
- Slows gastric emptying.
- Enhances glucose-dependent insulin secretion.
- Reduces hepatic glucose output.
- Has documented cardiovascular benefit in trials like SELECT.
Cagrilintide (amylin receptor agonist).
- Activates amylin receptors (calcitonin receptor + RAMP complexes) in the area postrema and other brainstem satiety centers.
- Slows gastric emptying via a mechanism distinct from GLP-1 (vagal rather than direct enteric).
- Suppresses postprandial glucagon release.
- Promotes satiety via pathways that do not appear to downregulate in response to chronic GLP-1 dosing.
The combined effect is additive (and possibly slightly synergistic) on appetite suppression and weight loss, because the two drugs engage distinct receptor systems. Importantly, the combination does not simply double the GLP-1-class side effects, because cagrilintide does not act through GLP-1 receptors.
The Clinical and Experimental Evidence
Cagrilintide monotherapy. Before the combination trials, cagrilintide was tested as a standalone drug. Enebo et al. (2021) published results in The Lancet from a Phase 1b / early Phase 2 study showing that cagrilintide alone produced around 6–10% weight loss over 26 weeks, dose-dependently, with a tolerability profile similar to GLP-1 agonists. This established proof-of-concept for a weekly amylin analog.
Phase 2 CagriSema combination. A Phase 2 trial in adults with type 2 diabetes, reported in 2022, showed that CagriSema produced weight loss of roughly 15–17% at 32 weeks — strong numbers, and better than semaglutide alone — with HbA1c reductions consistent with a solid incretin effect. This was the data that set up the Phase 3 program.
Phase 3 REDEFINE-1 (obesity, December 2024). The pivotal trial. REDEFINE-1 randomized adults with obesity or overweight without type 2 diabetes to CagriSema, cagrilintide alone, semaglutide alone, or placebo, over 68 weeks. The headline results:
- CagriSema group: approximately 22.7% mean body weight reduction at 68 weeks.
- Semaglutide-alone arm: in line with prior semaglutide trials (mid-teens percent loss).
- Cagrilintide-alone arm: in the ~12% range.
- Placebo: low single-digit percent loss.
In absolute terms, 22.7% is the highest weight loss Novo Nordisk has ever shown in a Phase 3 obesity trial — better than Wegovy, better than liraglutide, better than anything else in their portfolio. In relative terms, it fell short of the internal expectation of ~25% that Novo Nordisk had telegraphed to investors, and it did not clearly beat tirzepatide's results from SURMOUNT-1, which had landed in the ~21% range at a similar timepoint. The stock reaction was sharp and negative.
A secondary finding from REDEFINE-1 that complicated the narrative: a substantial proportion of patients had not reached maximum dose by the end of the trial, in part because the titration schedule was conservative and many participants did not push to the highest dose. Post-hoc analyses of the subgroup that did reach the top dose showed weight loss closer to 25%, which hints that the real-world ceiling for CagriSema is higher than the ITT number suggests.
REDEFINE-2 (type 2 diabetes). A parallel Phase 3 trial in patients with type 2 diabetes and obesity is running, with weight-loss expectations somewhat lower (as is typical — patients with diabetes tend to lose less weight on incretins than those without).
Applications
If CagriSema reaches approval, the expected applications are:
- Chronic weight management in adults with obesity or overweight with weight-related comorbidities, as a once-weekly subcutaneous injection.
- Type 2 diabetes with obesity, based on REDEFINE-2 data.
- Possible cardiovascular indications if the outcomes program supports them.
The positioning question is more interesting than the indication. CagriSema will launch into a market where Wegovy (semaglutide) and Zepbound (tirzepatide) are already entrenched, and where multiple higher-efficacy candidates — retatrutide (Lilly, triple agonist, ~24% in Phase 2), survodutide (BI/Zealand, dual GLP-1/glucagon, strong Phase 2), and oral small-molecule GLP-1s — are in late development. Novo's bet with CagriSema is that the dual-mechanism (GLP-1 + amylin) approach has a differentiated tolerability profile and may play well in patients who cannot tolerate the highest tirzepatide doses.
Connection to Gene Editing
The CagriSema story connects to gene editing through the broader theme of how we develop and deliver metabolic therapies. The amylin biology that cagrilintide exploits was first understood through classical receptor pharmacology, but modern studies of the amylin receptor — which is actually the calcitonin receptor paired with receptor activity-modifying proteins (RAMPs) — have been sharpened by CRISPR knockout studies in mice and cell lines. CRISPR-based functional genomics has become a standard tool for validating which receptors and pathways are essential for satiety, energy balance, and insulin secretion.
Looking forward, a more speculative but real research direction is gene therapy for obesity. If repeated weekly injections of GLP-1 and amylin analogs can produce 20%+ weight loss, what would happen if a one-time AAV delivery edited liver or muscle cells to express these peptides endogenously at therapeutic levels? Preclinical work is actively exploring this, and while it is years away from human trials, it is the logical long-term trajectory. For the foundational tools behind these experiments, see what is CRISPR.
And the metabolic-aging connection stays relevant: obesity, type 2 diabetes, fatty liver disease, and cardiovascular disease all fit into the "deregulated nutrient sensing" axis of the hallmarks of aging, which is one of the most pharmacologically tractable targets in the entire longevity framework.
Limitations and Regulatory Status
Honest caveats on CagriSema:
- Missed expectations, not missed efficacy. 22.7% weight loss is a real, clinically meaningful result. The disappointment was relative to Novo Nordisk's internal bar, not to real-world standards.
- Titration issues. The REDEFINE-1 trial design led to many patients not reaching the top dose, which likely depressed the headline number. Real-world performance with better titration could be higher.
- Competitive pressure. Retatrutide and survodutide are both showing results that may match or exceed CagriSema. The obesity drug market is entering a phase where being second-best on efficacy is a meaningful commercial problem.
- GI tolerability. Like all incretin-class products, nausea, vomiting, and diarrhea are common early side effects. The amylin component may add its own mild nausea contribution.
- Cost and access. Novo Nordisk's existing products have been expensive and supply-constrained. CagriSema will enter the same reimbursement and access environment.
- Long-term durability unknown. 68 weeks is a snapshot. How weight loss maintenance looks at 3–5 years of CagriSema is an open question, as it is for all chronic weight-management drugs.
FAQ
What does CagriSema contain?
A fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist), delivered as a single once-weekly subcutaneous injection.
How much weight did people lose in REDEFINE-1?
The intention-to-treat analysis at 68 weeks showed approximately 22.7% mean body weight reduction in the CagriSema arm. Subgroup analyses of patients who reached the top dose showed numbers closer to 25%.
Why was the market reaction negative?
Novo Nordisk had signaled an internal expectation closer to 25%, and 22.7% — while strong in absolute terms — fell below that bar and did not clearly beat tirzepatide's SURMOUNT-1 data. The stock declined sharply on the readout.
How does CagriSema compare to Zepbound (tirzepatide)?
On headline weight-loss numbers they are comparable, with tirzepatide's SURMOUNT-1 landing around 21% and CagriSema's REDEFINE-1 landing at 22.7%. There is no direct head-to-head trial. Different mechanism (GLP-1/GIP vs GLP-1/amylin) may produce different tolerability profiles in individual patients.
Is cagrilintide the same as pramlintide?
No. Pramlintide (Symlin) is the first-generation amylin analog, requires three-times-daily dosing, and had limited uptake. Cagrilintide is engineered for weekly dosing and does not fibrillate the way earlier amylin analogs did.
When could CagriSema be approved?
With REDEFINE-1 readout behind it and REDEFINE-2 running in parallel, regulatory submissions are expected in 2026–2027, with potential approval in the late 2020s.
